Literature DB >> 7907481

Adverse effects of antipsychotic drugs.

A K Malhotra1, R E Litman, D Pickar.   

Abstract

Since the introduction of chlorpromazine in the 1950s, neuroleptic medications have been the mainstay of treatment of schizophrenia and other psychotic disorders. These medications do not always lead to complete remission of symptoms but they have allowed many patients to lead more productive and satisfying lives away from the restrictions of chronic hospitalisation. However, neuroleptics are associated with a number of adverse effects that can compromise their effectiveness. Extrapyramidal adverse effects include acute dystonic reactions, neuroleptic-induced Parkinsonism and akathisia. They can often be treated with neuroleptic dose reduction, addition of anticholinergic or beta-blocking agents, or medication change. Later-onset movement disorders such as tardive dyskinesia or dystonia require careful evaluation and may be treated with dose reduction or change of neuroleptic to an atypical agent. Potentially fatal reactions such as agranulocytosis and neuroleptic malignant syndrome can rarely occur and often require significant medical intervention. Clozapine offers some advantages over 'typical' neuroleptics but has a unique adverse effect profile which includes agranulocytosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7907481     DOI: 10.2165/00002018-199309060-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  52 in total

1.  A prospective analysis of 24 episodes of neuroleptic malignant syndrome.

Authors:  P Rosebush; T Stewart
Journal:  Am J Psychiatry       Date:  1989-06       Impact factor: 18.112

2.  Risk factors for neuroleptic malignant syndrome. A case-control study.

Authors:  P E Keck; H G Pope; B M Cohen; S L McElroy; A A Nierenberg
Journal:  Arch Gen Psychiatry       Date:  1989-10

3.  EEG profile studies of clozapine in volunteers and psychiatric patients.

Authors:  M Fink; P Irwin; P Weinhold
Journal:  Pharmakopsychiatr Neuropsychopharmakol       Date:  1979-03

4.  Why do schizophrenic patients refuse to take their drugs?

Authors:  T Van Putten
Journal:  Arch Gen Psychiatry       Date:  1974-07

5.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

6.  Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia.

Authors:  M H Chakos; D I Mayerhoff; A D Loebel; J M Alvir; J A Lieberman
Journal:  Psychopharmacol Bull       Date:  1992

7.  Acute dystonia during fixed-dose neuroleptic treatment.

Authors:  H Singh; D F Levinson; G M Simpson; E S Lo; E Friedman
Journal:  J Clin Psychopharmacol       Date:  1990-12       Impact factor: 3.153

8.  Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.

Authors:  D Pickar; R R Owen; R E Litman; E Konicki; R Gutierrez; M H Rapaport
Journal:  Arch Gen Psychiatry       Date:  1992-05

Review 9.  Neuroleptic malignant syndrome or parkinsonism hyperpyrexia syndrome.

Authors:  M A Granner; G F Wooten
Journal:  Semin Neurol       Date:  1991-09       Impact factor: 3.420

10.  Akathisia with haloperidol and thiothixene.

Authors:  T Van Putten; P R May; S R Marder
Journal:  Arch Gen Psychiatry       Date:  1984-11
View more
  6 in total

Review 1.  First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

Authors:  Deanna L Kelly; Robert R Conley; William T Carpenter
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  [Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview].

Authors:  B Voss; R Thienel; S Leucht; T Kircher
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

3.  Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response.

Authors:  Renan P Souza; Marco A Romano-Silva; Jeffrey A Lieberman; Herbert Y Meltzer; Albert H C Wong; James L Kennedy
Journal:  Psychopharmacology (Berl)       Date:  2008-05-26       Impact factor: 4.530

4.  Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia.

Authors:  Koichiro Fujimaki; Terumichi Takahashi; Shigeru Morinobu
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

Review 5.  A Neurophysiological Perspective on a Preventive Treatment against Schizophrenia Using Transcranial Electric Stimulation of the Corticothalamic Pathway.

Authors:  Didier Pinault
Journal:  Brain Sci       Date:  2017-03-28

6.  HTR1A, HTR1B, HTR2A, HTR2C and HTR6 Gene Polymorphisms and Extrapyramidal Side Effects in Haloperidol-Treated Patients with Schizophrenia.

Authors:  Mirko Grubor; Maja Zivkovic; Marina Sagud; Matea Nikolac Perkovic; Alma Mihaljevic-Peles; Nela Pivac; Dorotea Muck-Seler; Dubravka Svob Strac
Journal:  Int J Mol Sci       Date:  2020-03-28       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.